Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.
3.
4.

Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.

Naik S, Galyon GD, Jenks NJ, Steele MB, Miller AC, Allstadt SD, Suksanpaisan L, Peng KW, Federspiel MJ, Russell SJ, LeBlanc AK.

Mol Cancer Ther. 2018 Jan;17(1):316-326. doi: 10.1158/1535-7163.MCT-17-0432. Epub 2017 Nov 20.

5.

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.

Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, Zhou Y, Federspiel MJ, Gertz MA, Hayman S, Buadi F, O'Connor M, Lowe VJ, Peng KW, Russell SJ.

Leukemia. 2017 Dec;31(12):2791-2798. doi: 10.1038/leu.2017.120. Epub 2017 Apr 25.

6.

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E.

Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035. Review.

7.

Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Zhang L, Steele MB, Jenks N, Grell J, Behrens M, Nace R, Naik S, Federspiel MJ, Russell SJ, Peng KW.

Mol Ther. 2016 Dec;24(12):2109-2117. doi: 10.1038/mt.2016.167. Epub 2016 Sep 26.

8.

Recombinant mumps virus as a cancer therapeutic agent.

Ammayappan A, Russell SJ, Federspiel MJ.

Mol Ther Oncolytics. 2016 Aug 10;3:16019. doi: 10.1038/mto.2016.19. eCollection 2016.

9.

Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.

Zhang L, Steele MB, Jenks N, Grell J, Suksanpaisan L, Naik S, Federspiel MJ, Lacy MQ, Russell SJ, Peng KW.

Hum Gene Ther Clin Dev. 2016 Sep;27(3):111-22. doi: 10.1089/humc.2016.061.

10.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.

Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK, Mesev E, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

Oncotarget. 2015 Oct 20;6(32):33165-77. doi: 10.18632/oncotarget.5320.

11.

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.

Iankov ID, Kurokawa CB, D'Assoro AB, Ingle JN, Domingo-Musibay E, Allen C, Crosby CM, Nair AA, Liu MC, Aderca I, Federspiel MJ, Galanis E.

Cancer Gene Ther. 2015 Sep;22(9):438-44. doi: 10.1038/cgt.2015.36. Epub 2015 Aug 14.

12.

Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.

Yu C, Pike GM, Rinkoski TA, Correia C, Kaufmann SH, Federspiel MJ.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9860-5. doi: 10.1073/pnas.1414754112. Epub 2015 Jul 27.

13.

Model of the TVA receptor determinants required for efficient infection by subgroup A avian sarcoma and leukosis viruses.

Melder DC, Pike GM, VanBrocklin MW, Federspiel MJ.

J Virol. 2015 Feb;89(4):2136-48. doi: 10.1128/JVI.02339-14. Epub 2014 Dec 3.

14.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

15.

Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Patel MR, Jacobson BA, Belgum H, Raza A, Sadiq A, Drees J, Wang H, Jay-Dixon J, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

J Thorac Oncol. 2014 Aug;9(8):1101-10. doi: 10.1097/JTO.0000000000000214.

16.

Remission of disseminated cancer after systemic oncolytic virotherapy.

Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A.

Mayo Clin Proc. 2014 Jul;89(7):926-33. doi: 10.1016/j.mayocp.2014.04.003. Epub 2014 May 14.

17.

Vesiculovirus neutralization by natural IgM and complement.

Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ.

J Virol. 2014 Jun;88(11):6148-57. doi: 10.1128/JVI.00074-14. Epub 2014 Mar 19. Erratum in: J Virol. 2015 Feb;89(3):1945-6.

18.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

19.

Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.

LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.

20.

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.

Yarde DN, Naik S, Nace RA, Peng KW, Federspiel MJ, Russell SJ.

Cancer Gene Ther. 2013 Nov;20(11):616-21. doi: 10.1038/cgt.2013.63. Epub 2013 Nov 1.

21.

Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.

Kurisetty VV, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR.

Head Neck. 2014 Nov;36(11):1619-27. doi: 10.1002/hed.23502. Epub 2014 Feb 1.

22.

Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.

Bailey K, Kirk A, Naik S, Nace R, Steele MB, Suksanpaisan L, Li X, Federspiel MJ, Peng KW, Kirk D, Russell SJ.

PLoS One. 2013 Sep 11;8(9):e73759. doi: 10.1371/journal.pone.0073759. eCollection 2013.

23.

Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

Iankov ID, Federspiel MJ, Galanis E.

Vaccine. 2013 Oct 1;31(42):4795-801. doi: 10.1016/j.vaccine.2013.07.085. Epub 2013 Aug 12.

24.

Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.

Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM.

J Hepatol. 2013 Nov;59(5):999-1006. doi: 10.1016/j.jhep.2013.07.010. Epub 2013 Jul 16.

25.

Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.

Touchefeu Y, Khan AA, Borst G, Zaidi SH, McLaughlin M, Roulstone V, Mansfield D, Kyula J, Pencavel T, Karapanagiotou EM, Clayton J, Federspiel MJ, Russell SJ, Garrett M, Collins I, Harrington KJ.

Radiother Oncol. 2013 Jul;108(1):24-31. doi: 10.1016/j.radonc.2013.05.036. Epub 2013 Jul 9.

PMID:
23849174
26.

Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW.

J Transl Med. 2013 Jan 24;11:20. doi: 10.1186/1479-5876-11-20.

27.

PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ.

J Virol. 2013 Apr;87(7):3752-9. doi: 10.1128/JVI.02832-12. Epub 2013 Jan 16. Erratum in: J Virol. 2015 Feb;89(4):2453.

28.

Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.

Iankov ID, Penheiter AR, Griesmann GE, Carlson SK, Federspiel MJ, Galanis E.

Virus Res. 2013 Mar;172(1-2):15-23. doi: 10.1016/j.virusres.2012.12.002. Epub 2012 Dec 21.

29.

Progress in gene therapy for prostate cancer.

Ahmed KA, Davis BJ, Wilson TM, Wiseman GA, Federspiel MJ, Morris JC.

Front Oncol. 2012 Nov 19;2:172. doi: 10.3389/fonc.2012.00172. eCollection 2012.

30.

Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.

Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria JN, Domingo E, Federspiel MJ, Galanis E.

Gene Ther. 2013 Apr;20(4):444-9. doi: 10.1038/gt.2012.62. Epub 2012 Aug 23.

31.

Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ, Dispenzieri A, Russell SJ.

Gene Ther. 2013 Mar;20(3):255-61. doi: 10.1038/gt.2012.31. Epub 2012 Apr 5.

32.

Curative one-shot systemic virotherapy in murine myeloma.

Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ.

Leukemia. 2012 Aug;26(8):1870-8. doi: 10.1038/leu.2012.70. Epub 2012 Mar 19.

33.

Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.

Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E.

Mol Ther. 2012 Jun;20(6):1139-47. doi: 10.1038/mt.2012.4. Epub 2012 Feb 14.

34.

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.

Liu YP, Tong C, Dispenzieri A, Federspiel MJ, Russell SJ, Peng KW.

Cancer Gene Ther. 2012 Mar;19(3):202-11. doi: 10.1038/cgt.2011.82. Epub 2011 Nov 25.

35.

Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors.

Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK.

Gene Ther. 2012 Mar;19(3):279-87. doi: 10.1038/gt.2011.107. Epub 2011 Jul 14.

36.

Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions.

Hadac EM, Federspiel MJ, Chernyy E, Tuzikov A, Korchagina E, Bovin NV, Russell S, Henry SM.

J Virol Methods. 2011 Sep;176(1-2):78-84. doi: 10.1016/j.jviromet.2011.06.005. Epub 2011 Jun 14.

PMID:
21703308
37.

Manufacture of measles viruses.

Langfield KK, Walker HJ, Gregory LC, Federspiel MJ.

Methods Mol Biol. 2011;737:345-66. doi: 10.1007/978-1-61779-095-9_14.

PMID:
21590404
38.

Simple, automated, high resolution mass spectrometry method to determine the disulfide bond and glycosylation patterns of a complex protein: subgroup A avian sarcoma and leukosis virus envelope glycoprotein.

Pike GM, Madden BJ, Melder DC, Charlesworth MC, Federspiel MJ.

J Biol Chem. 2011 May 20;286(20):17954-67. doi: 10.1074/jbc.M111.229377. Epub 2011 Mar 23.

39.

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ.

Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26.

40.

Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.

Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW.

Hum Gene Ther. 2010 Apr;21(4):451-62. doi: 10.1089/hum.2009.111.

41.

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.

Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E.

Breast Cancer Res Treat. 2010 Aug;122(3):745-54. doi: 10.1007/s10549-009-0602-z. Epub 2009 Nov 6.

42.

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E.

Mol Ther. 2009 Dec;17(12):2041-8. doi: 10.1038/mt.2009.218. Epub 2009 Sep 22.

43.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM.

Hum Gene Ther. 2010 Jan;21(1):51-64. doi: 10.1089/hum.2009.088.

44.
45.
46.

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.

Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C, Shelton SE, Soeffker D, Zollman P, Federspiel MJ, Blanco M, Galanis E.

Hum Gene Ther. 2008 Jul;19(7):690-8. doi: 10.1089/hum.2008.035.

47.

Stabilization of measles virus for vaccine formulation.

Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR.

Hum Vaccin. 2008 Sep-Oct;4(5):350-9. Epub 2008 Sep 7.

PMID:
18382143
48.

Cysteines flanking the internal fusion peptide are required for the avian sarcoma/leukosis virus glycoprotein to mediate the lipid mixing stage of fusion with high efficiency.

Delos SE, Brecher MB, Chen Z, Melder DC, Federspiel MJ, White JM.

J Virol. 2008 Mar;82(6):3131-4. doi: 10.1128/JVI.02266-07. Epub 2008 Jan 9.

49.

Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation.

Rao VP, Miyagi N, Ricci D, Carlson SK, Morris JC 3rd, Federspiel MJ, Bailey KR, Russell SJ, McGregor CG.

Transplantation. 2007 Dec 27;84(12):1662-6. doi: 10.1097/01.tp.0000295932.26883.ba.

PMID:
18165779
50.

Supplemental Content

Loading ...
Support Center